
NCTN Lymphoma Trials Portfolio (Open as of 11/15/2025)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



NCTN Lymphoma Trials (Open as of 11/15/2025)

Protocol Number	Phase	Protocol Title
		Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by
A051901	ı	Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
		A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated
A051902	П	CD30 Negative Peripheral T-Cell Lymphomas
		A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront
A052101	Ш	Treatment in Older Patients with Mantle Cell Lymphoma
		A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology
AHOD2131	Ш	Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
		A Phase 2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or
		Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma with MYC
EA4231	П	and BCL2 Rearrangements (HGBCL-DH-BCL2)
		A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with
		Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy
EA4232	Ш	(PTCL-STAT)
		A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual
EA9213	П	Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL)
		A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) In Patients with Relapsed/Refractory T-
S1905	II	Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
		A Phace II/III Pandamized Study of P. MiniCHOD with or Without CC 496 (Oral Azacitidina) in Participants Ago
		A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age
S1918	11/111	75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma,
21319	11/111	Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy
S1925	Ш	with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic
31925	1111	Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study A Phase II Randomized Study of Ibrutinib and Rituximab with or Without Venetoclax in Previously Untreated
C200F	l.,	,
S2005	II	Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
C2444	l.,	A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For
S2114	II	Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
C2207		Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in
S2207	II	Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma
S2308	Ш	Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
32300	1111	namuomizeu riiase iii stuuy oi iviosunetuzumau vs. nituximau ioi tow Tumor Buruen Follicular Lymphoma